SCHEMBL2244099

SCHEMBL2244099

C[C@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)[O-].C[C@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)[O-].[Cu+2]

nearest known ligand 0.44

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 16/20 0.44
▸ NPY1R P25929 10/20 0.44
▸ NPY5R Q15761 9/20 0.44
▸ NPY2R P49146 6/20 0.44
▸ SIRT6 Q8N6T7 1/20 0.42
▸ SIRT1 Q96EB6 1/20 0.42
▸ NMT2 O60551 1/20 0.42
▸ NMT1 P30419 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4588680 0.98 NPY4R (0.44) NPY4RNPY1RNPY5RNPY2RSIRT6
SCHEMBL2811185 0.92 NPY4R (0.42) NPY4RNPY1RNPY5RNPY2R
SCHEMBL4587357 0.89 NPY4R (0.42) NPY4RNPY1RNPY5RNPY2R
SCHEMBL30590516 0.88 NPY4R (0.46) NPY4RNPY1RNPY5RNPY2RSIRT6
SCHEMBL5598700 0.88 NPY4R (0.46) NPY4RNPY1RNPY5RNPY2RSIRT6
SCHEMBL5598707 0.88 NPY4R (0.46) NPY4RNPY1RNPY5RNPY2RSIRT6
SCHEMBL2241867 0.87 NMT1 (0.42) NPY4RNPY1RNPY5RNPY2RSIRT6
SCHEMBL4588675 0.87 NPY4R (0.45) NPY4RNPY1RNPY5RNPY2RSIRT6
SCHEMBL2244094 0.87 NPY4R (0.45) NPY4RNPY1RNPY5RNPY2RSIRT6
SCHEMBL30800714 0.86 NPY4R (0.44) NPY4RNPY1RNPY5RNPY2RSIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110206790-A1 Antimicrobial Foamable Soaps OHSO CLEAN, INC 2011-08-25 — — US disclosed
EP-2350252-A2 ANTIMICROBIAL FOAMABLE SOAPS Ohso Clean, Inc. (US) 2011-08-03 — — EP disclosed
US-20100249042-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS PROCYTE CORPORATION (US) 2010-09-30 — — US disclosed
WO-2010059366-A2 ANTIMICROBIAL FOAMABLE SOAPS OHSO CLEAN, INC. (US) 2010-05-27 — — WO disclosed
EP-1613302-B1 PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO PROCYTE CORP (US) 2009-12-23 — — EP disclosed
US-7179789-B2 Compositions and methods for treatment of rosacea PROCYTE CORPORATION (US) 2007-02-20 — — US disclosed
US-7128923-B2 Preserved and stable compositions containing peptide copper complexes and method related thereto PROCYTE CORPORATION (US) 2006-10-31 — — US disclosed
US-20060052287-A1 Polyethylene glycol - peptide copper complexes and compositions and methods related thereto PROCYTE CORPORATION (US) 2006-03-09 — — US disclosed
US-20050260275-A1 Encapsulated peptide copper complexes and compositions and methods related thereto PROCYTE CORPORATION (US) 2005-11-24 — — US disclosed
US-20050209130-A1 Compositions and methods for treatment of rosacea PROCYTE CORPORATION (US) 2005-09-22 — — US disclosed
US-20050197282-A1 for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics PROCYTE CORPORATION (US) 2005-09-08 — — US disclosed
US-6927206-B2 Compositions and methods for treatment of rosacea PROCYTE CORPORATION (US) 2005-08-09 — — US disclosed
US-6927205-B2 Compositions and methods for treatment of psoriasis PROCYTE CORPORATION (US) 2005-08-09 — — US disclosed
EP-0765152-B1 STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES PROCYTE CORP (US) 2001-11-07 — — EP disclosed
EP-0765152-A1 STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES PROCYTE CORPORATION (US) 1997-04-02 — — EP disclosed
WO-1995035085-A1 STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES PROCYTE CORPORATION (US) 1995-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209130-A1 Compositions and methods for treatment of rosacea CUTA, AOC1, RCN1 NPY4R 811/4885NPY1R 171/4885NPY5R 380/4885
US-20060052287-A1 Polyethylene glycol - peptide copper complexes and compositions and methods related thereto NGLY1, CUTA, TFRC NPY4R 1065/4885NPY1R 269/4885NPY5R 596/4885
US-20100249042-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS CUTA, TYR, EYA3 NPY4R 785/4885NPY1R 300/4885NPY5R 402/4885
US-20050197282-A1 for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics PTH1R, TSLP, CYP27B1 NPY4R 797/4885NPY1R 936/4885NPY5R 1358/4885
US-20050260275-A1 Encapsulated peptide copper complexes and compositions and methods related thereto NGLY1, CUTA, CTRC NPY4R 496/4885NPY1R 170/4885NPY5R 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback